International Clinical Trial: A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dnth103 in adults with chronic inflammatory demyelinating polyneuropathy (captivate)

Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122401) titled 'A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dnth103 in adults with chronic inflammatory demyelinating polyneuropathy (captivate)' on April 13.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Huashan Hospital, Fudan University

Condition: Adults with chronic inflammatory demyelinating polyneuropathy

Intervention: DNTH103 300 mg:DNTH103 300 mg placebo:placebo

Recruitment Status: Not Recruiting

Phase: 3

Date of First Enrollment: 2026-04-30

Target Sample Size: DNTH103 300 mg:64;placebo:64;DNTH103 600 mg:64;

Countries of R...